ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision makingHans‐Joachim Schmoll, Andrés Cervantes, Eric Van Cutsem et al.|Annals of Oncology|2012Cited by 1.5k
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trialAimery de Gramont, Paulo M. Hoff, Malcolm J. Moore et al.|The Lancet Oncology|2012Cited by 526
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study groupDominik Paul Modest, Anke Reinacher‐Schick, Ingrid Ricard et al.|Annals of Oncology|2016Cited by 344
Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upJan Oldenburg, Vesa Kataja, Sophie D. Fosså et al.|Annals of Oncology|2013Cited by 280
Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neckG. Catimel, Jan B. Vermorken, Jaap Verweij et al.|Annals of Oncology|1994Cited by 259